Ketorolac/phenylephrine ophthalmic

Drug Overview

In the highly technical field of Ophthalmology, surgical precision is often dependent on the physiological stability of the eye during the procedure. The combination of Ketorolac/phenylephrine ophthalmic represents a sophisticated Targeted Therapy used primarily in the operating room. This medication is a dual-action agent belonging to two distinct drug classes: Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) and Mydriatic (pupil-dilating) agents.

Unlike traditional eye drops used by patients at home, this specific combination is designed for surgical integration. It is added to the irrigation fluid used during cataract surgery or intraocular lens replacement. By addressing both inflammation and pupil diameter simultaneously, it provides a stable environment for the surgeon while improving the post-operative experience for the patient.

• Generic Name: Ketorolac Tromethamine and Phenylephrine Hydrochloride
• US Brand Name: OMIDRIA
• Drug Class: NSAID / Mydriatic
• Route of Administration: Intraocular Irrigation (added to balanced salt solution during surgery)
• FDA Approval Status: FDA-approved for use during cataract surgery or intraocular lens replacement to maintain intraoperative miosis and reduce postoperative ocular pain.
  
  Find detailed surgical information on ketorolac/phenylephrine ophthalmic, essential for maintaining pupil dilation and preventing intraoperative pain.

What Is It and How Does It Work? (Mechanism of Action)

The success of a cataract procedure depends on a wide, stable pupil. However, the very act of surgical trauma making an incision or using ultrasound energy (phacoemulsification) triggers the eye to defend itself. This defense mechanism usually involves pupil constriction (miosis) and the release of inflammatory markers. The combination of Ketorolac and Phenylephrine works at the molecular level to counteract these responses in real-time.

Ketorolac: The Anti-Inflammatory Shield

Ketorolac is a potent NSAID that works by inhibiting the cyclooxygenase enzymes (COX-1 and COX-2). When the eye is surgically manipulated, it releases arachidonic acid, which these enzymes convert into prostaglandins. Prostaglandins are the primary signaling molecules that cause pain and, more critically, cause the iris sphincter muscle to contract. By blocking the production of prostaglandins at the source within the anterior chamber, Ketorolac prevents the “miotic trigger,” keeping the iris relaxed and significantly reducing the patient’s sensation of pain during and after the procedure.

Phenylephrine: The Alpha-Adrenergic Activator

Phenylephrine is a powerful Mydriatic agent that acts as an alpha-1 adrenergic receptor agonist. It targets the radial dilator muscle of the iris. When these receptors are activated, the muscle contracts, causing the pupil to dilate. Because this medication is delivered continuously through the irrigation fluid, it maintains a steady concentration of the drug on the iris throughout the entire surgery. This prevents the “floppy iris” syndrome or sudden constriction that can occur when surgeons rely solely on pre-operative drops.

Together, these two ingredients create a synergistic effect: one prevents the muscle from squeezing shut (Ketorolac), while the other actively keeps the window open (Phenylephrine).

FDA-Approved Clinical Indications

Primary Indication

The primary indication for this combination is for use during Cataract Surgery or Intraocular Lens (IOL) Replacement. It is specifically indicated to:

1. Maintain Intraoperative Miosis: Ensuring the pupil does not shrink during the delicate steps of removing the natural lens.
2. Reduce Postoperative Pain: Blocking pain receptors and inflammatory cascades before they can cause discomfort in the recovery room.

Other Approved & Off-Label Uses

While its primary label is specific to lens-based surgeries, its utility as an NSAID / Mydriatic blend has led to interest in other areas of anterior segment surgery.

• Primary Ophthalmology Indications:
  • Cataract Extraction: The standard application to ensure a safe surgical field and preserve visual acuity by preventing surgical complications.
  • Intraocular Lens Exchange: Used when a previously implanted lens must be replaced or repositioned, requiring prolonged pupil dilation.
  • Refractive Lens Exchange (RLE): Utilized in clear lens extraction for vision correction to maximize the safety of the procedure.
  • Complicated Anterior Segment Surgery: Often used off-label in cases involving iris hooks or small-pupil management to stabilize the iris diaphragm.

Dosage and Administration Protocols

This medication is not intended for self-administration by the patient. It is a concentrated solution that must be diluted by surgical staff and used as a part of the intraocular irrigation system.

Administration Instructions:

• Preparation: The 4 mL vial must be withdrawn using a sterile needle and injected into a 500 mL bag of Balanced Salt Solution (BSS).
• Timing: The diluted solution is used for the duration of the surgical procedure.
• Single Use: Any remaining solution in the irrigation bag must be discarded after the procedure.
• Storage: The concentrated vial should be stored away from light to prevent the degradation of Phenylephrine.

Dosage must be individualized by a qualified healthcare professional.

Clinical Efficacy and Research Results

Clinical trials conducted between 2018 and 2026 have consistently shown that the use of Ketorolac/Phenylephrine irrigation significantly improves surgical outcomes compared to standard irrigation fluid.

Key Data Points:

• Miosis Prevention: In pivotal Phase III trials, only 4% of patients using this NSAID / Mydriatic combination experienced a pupil diameter of less than 6 mm during surgery, compared to over 22% in the placebo group.
• Pain Reduction: Data shows that approximately 50% more patients reported being “completely pain-free” in the immediate hours following surgery when this combination was used.
• Surgical Time: Some studies suggest a reduction in surgical time by an average of 1.5 to 2 minutes in complex cases, as the surgeon does not have to stop to add additional dilating medications or mechanical expansion devices.
• Visual Acuity (BCVA): While the drug itself doesn’t change the final BCVA, it prevents intraoperative complications (like iris trauma) that could otherwise limit the patient’s final visual potential.
• Cystoid Macular Edema (CME): Recent research (2023-2025) has explored whether the early “loading” of Ketorolac into the eye during surgery reduces the incidence of post-operative retinal swelling (CME), with some data showing a 5% to 7% decrease in CRT (Central Retinal Thickness) compared to controls.

Safety Profile and Side Effects

Black Box Warning: There is no Black Box Warning for Ketorolac/Phenylephrine ophthalmic solution.

Common Side Effects (>10%)

Because the drug is used during surgery, many side effects are difficult to distinguish from the standard recovery process of a cataract operation.

• Anterior Chamber Inflammation: Mild redness or “cells” in the eye fluid post-operatively.
• Increased Intraocular Pressure (IOP): Temporary spikes in pressure after surgery.
• Posterior Capsule Opacification: A common long-term occurrence after cataract surgery, though not directly caused by the drug.
• Blurred Vision: Typical for the first 24-48 hours after a lens procedure.

Serious Adverse Events

• Systemic Absorption: In rare cases, Phenylephrine can be absorbed systemically, potentially leading to a temporary increase in blood pressure or heart rate (tachycardia).
• Corneal Edema: Swelling of the clear front part of the eye if the irrigation is prolonged.
• Cystoid Macular Edema (CME): While the drug aims to prevent this, any intraocular surgery carries a risk of retinal swelling.
• Endophthalmitis: A risk associated with any intraocular surgery, though not the drug itself.

Management Strategies:

Surgeons monitor the patient’s vitals (blood pressure and heart rate) during surgery to manage any systemic response to Phenylephrine. Post-operative care involves standard topical steroids and NSAIDs to ensure the inflammatory response initiated by the surgery is fully suppressed.

Research Areas

Direct Clinical Connections

Active research (2024-2026) is investigating the drug’s effect on Aqueous Outflow Resistance. Some scientists believe that by reducing prostaglandin release during surgery, we might prevent the early “clogging” of the eye’s drainage system, leading to more stable intraocular pressure in the first 24 hours. There is also specific interest in Goblet Cell Density and ocular surface health; by reducing the need for multiple pre-operative dilating drops (which often contain harsh preservatives like BAK), this intraoperative approach may better preserve the tear film.

Generalization

As the industry moves toward Preservative-Free and Sustained-Release options, researchers are looking into whether a version of this combination could be delivered via a Sustained-Release Intraocular Implant during surgery. This would provide anti-inflammatory coverage for several weeks, potentially eliminating the need for patients to use eye drops at home.

Severe Disease & Surgical Integration

In patients with end-stage glaucoma undergoing cataract surgery, pupil stability is vital because their eyes are often already compromised. Research is ongoing to see if this Targeted Therapy reduces the risk of “spike” pressures in glaucoma patients by minimizing the overall surgical trauma.

Disclaimer: These studies regarding sustained-release implants and neuroprotection are currently in the preclinical phase and are not yet applicable to practical or professional clinical scenarios.

Patient Management and Clinical Protocols

Pre-treatment Assessment

Since this drug is used intraoperatively, the assessment happens during the surgical workup.

• Baseline Diagnostics: Accurate measurement of Baseline Visual Acuity and Tonometry (IOP).
• Ocular Imaging: Optical Coherence Tomography (OCT) to check for pre-existing macular holes or swelling.
• Screening: Patients are screened for a history of hypertension or sensitivity to Phenylephrine. It is also important to note if the patient is taking alpha-blockers (like Flomax), which can cause Intraoperative Floppy Iris Syndrome (IFIS).

Monitoring and Precautions

• Vigilance: Surgeons monitor the pupil size throughout the procedure. Post-operatively, clinicians monitor for “rebound” inflammation.
• Lifestyle: After surgery, patients are advised to use UV protection (sunglasses) because the eye will be sensitive to light, especially if the pupil remains slightly dilated for a few hours.
• Do’s and Don’ts:
  • DO tell your surgeon if you have ever had a heart condition or high blood pressure.
  • DO mention if you are taking medications for prostate health.
  • DON’T worry if your vision is blurry immediately after surgery; this is normal as the medication wears off.
  • DON’T rub your eye post-surgery, as this can increase inflammation.

Legal Disclaimer

This guide is provided for educational purposes only and does not constitute medical advice or a doctor-patient relationship. OMIDRIA is a prescription-only product used exclusively in a surgical setting. Clinical outcomes may vary based on individual patient health factors and surgical technique. Always consult with your ophthalmologist regarding the specific risks and benefits of medications used during your eye surgery. Information regarding FDA status and clinical trials is based on data available as of 2026.